Similar articles for PMID: 30642877

Year	Number of Results
2001	2
2004	4
2005	1
2006	3
2007	1
2008	1
2009	2
2010	2
2011	2
2012	5
2013	6
2014	5
2015	9
2016	8
2017	6
2018	6
2019	4
2020	1
2021	2
2022	2

1

Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities.

Estrada CC, Maldonado A, Mallipattu SK. Estrada CC, et al. J Am Soc Nephrol. 2019 Feb;30(2):187-200. doi: 10.1681/ASN.2018080853. Epub 2019 Jan 14. J Am Soc Nephrol. 2019. PMID: 30642877 Free PMC article. Review.

2

Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.

Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Virgili G, et al. Cochrane Database Syst Rev. 2017 Jun 22;6(6):CD007419. doi: 10.1002/14651858.CD007419.pub5. Cochrane Database Syst Rev. 2017. PMID: 28639415 Free PMC article. Updated. Review.

3

The role of anti-angiogenesis in non-small-cell lung cancer: an update.

Villaruz LC, Socinski MA. Villaruz LC, et al. Curr Oncol Rep. 2015 Jun;17(6):26. doi: 10.1007/s11912-015-0448-y. Curr Oncol Rep. 2015. PMID: 25947099 Free PMC article. Review.

4

Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.

Tie J, Desai J. Tie J, et al. Crit Rev Oncog. 2012;17(1):51-67. doi: 10.1615/critrevoncog.v17.i1.50. Crit Rev Oncog. 2012. PMID: 22471664 Review.

5

Promoter methylation status of VEGF receptor genes: a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells.

Kim J, Hwang J, Jeong H, Song HJ, Shin J, Hur G, Park YW, Lee SH, Kim J. Kim J, et al. Epigenetics. 2012 Feb;7(2):191-200. doi: 10.4161/epi.7.2.18973. Epigenetics. 2012. PMID: 22395469

6

Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer.

Barr MP, Gray SG, Gately K, Hams E, Fallon PG, Davies AM, Richard DJ, Pidgeon GP, O'Byrne KJ. Barr MP, et al. Mol Cancer. 2015 Feb 20;14:45. doi: 10.1186/s12943-015-0310-8. Mol Cancer. 2015. PMID: 25889301 Free PMC article.

7

Aflibercept: a novel VEGF targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple tumors.

Sharma T, Dhingra R, Singh S, Sharma S, Tomar P, Malhotra M, Bhardwaj TR. Sharma T, et al. Mini Rev Med Chem. 2013 Apr;13(4):530-40. doi: 10.2174/1389557511313040006. Mini Rev Med Chem. 2013. PMID: 23317499 Review.

8

Anti-VEGF Molecules for the Management of Diabetic Macular Edema.

Bandello F, Cicinelli MV, Parodi MB. Bandello F, et al. Curr Pharm Des. 2015;21(32):4731-7. doi: 10.2174/1381612821666150909095756. Curr Pharm Des. 2015. PMID: 26350530 Review.

9

Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.

Riondino S, Del Monte G, Fratangeli F, Guadagni F, Roselli M, Ferroni P. Riondino S, et al. Cardiovasc Hematol Agents Med Chem. 2017;15(1):3-16. doi: 10.2174/1871525715666170127101605. Cardiovasc Hematol Agents Med Chem. 2017. PMID: 28137223 Review.

10

Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes.

MacDonald DA, Martin J, Muthusamy KK, Luo JK, Pyles E, Rafique A, Huang T, Potocky T, Liu Y, Cao J, Bono F, Delesque N, Savi P, Francis J, Amirkhosravi A, Meyer T, Romano C, Glinka M, Yancopoulos GD, Stahl N, Wiegand SJ, Papadopoulos N. MacDonald DA, et al. Angiogenesis. 2016 Jul;19(3):389-406. doi: 10.1007/s10456-016-9515-8. Epub 2016 May 27. Angiogenesis. 2016. PMID: 27234973 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed